Regeneron Pharmaceuticals Inc

Regeneron’s next‑generation biologics strategy blends advanced protein engineering, AI‑driven discovery, and scalable manufacturing—fueling growth in oncology, immunology, and its core eye‑care hits.

Regeneron’s gene‑therapy REG‑HL1 earns FDA accelerated approval, offering free treatment for rare congenital hearing loss and setting a new standard for equitable, outcome‑based pricing in gene‑therapy development.

Regeneron’s FDA‑approved gene therapy Otarmeni offers a curative, no‑cost solution for rare otoferlin‑related hearing loss, backed by strong revenue potential and value‑based pricing.

Regeneron’s new pediatric Dupixent approval and cemdisiran’s Phase 3 success spotlight a strategic expansion into high‑margin biologics and breakthrough siRNA therapies, offering investors a nuanced view of revenue growth potential and market positi…

Regeneron’s upcoming investor webcasts highlight strategic partnerships, innovative retinal therapies, and value‑based pricing to secure growth amid a 7‑8% specialty‑drug market CAGR.

Regeneron’s new EU pediatric CSU approval for Dupixent and partnership with Telix in radiopharmaceuticals boost its precision‑medicine portfolio, creating fresh revenue streams and first‑mover advantage in unmet pediatric dermatology and targeted ca…

Regeneron’s latest earnings beat estimates, keep a low‑leveraged, liquid balance sheet, and a steady $0.94 quarterly dividend, showing solid health and room for future biotech growth.

Regeneron warns of a modest Q1 2026 R&D charge tied to its collaborative deals, revealing how AI-driven analytics can help pharma manage unpredictable contingent costs.

Regeneron’s Dupixent gains EU approval for children 2‑11 with chronic spontaneous urticaria, expanding its portfolio, boosting investor appeal, and reflecting a trend toward pediatric biologics.

Dupixent’s new EU pediatric CSU indication, backed by LIBERTY‑CUPID trials, promises first‑of‑its‑kind targeted relief for 2‑11‑year‑olds, boosting Regeneron’s market reach and patient care.